Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clozapine: The commitment to patient safety
Autore:
Alphs, LD; Anand, R;
Indirizzi:
Novartis Pharmaceut Corp, CNS Med Affairs, E Hanover, NJ 07936 USA Novartis Pharmaceut Corp E Hanover NJ USA 07936 , E Hanover, NJ 07936 USA
Titolo Testata:
JOURNAL OF CLINICAL PSYCHIATRY
, volume: 60, anno: 1999, supplemento:, 12
pagine: 39 - 42
SICI:
0160-6689(1999)60:<39:CTCTPS>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
INDUCED AGRANULOCYTOSIS; RISK; SCHIZOPHRENIA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Alphs, LD NovartisNJharmaceut Corp, CNS Med Affairs, 59 Route 10,701-106, E Hanover, Novartis Pharmaceut Corp 59 Route 10,701-106 E Hanover NJ USA 07936
Citazione:
L.D. Alphs e R. Anand, "Clozapine: The commitment to patient safety", J CLIN PSY, 60, 1999, pp. 39-42

Abstract

Clozapine represents the "gold standard" therapy for treatment-resistant schizophrenia including use for symptom reduction and use in patients intolerant of extrapyramidal side effects associated with other antipsychotics. Despite its clear benefit in these areas, its use has been associated with aserious, and sometimes life-threatening, risk for agranulocytosis. Effective white blood cell monitoring systems have been developed by Novartis affiliates across the world to ensure its safe use and to meet local health standards. The goals of the monitoring programs include: (1) weekly white blood cell monitoring during the initial months of therapy for early detection of severe leukopenia; (2) immediate discontinuation of clozapine if severe leukopenia is observed; (3) exclusion from reexposure to clozapine if a patient experiences clozapine-induced agranulocytosis; and (4) early cessationof treatment if hematologic guidelines are not followed ("no blood, no drug" policy). Together, these systems have demonstrated a worldwide reductionin the observed rate of agranulocytosis and in fatalities related to the emergence of agranulocytosis when rigorous monitoring systems are in place.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 00:35:14